1,548 results on '"Krueger, James G."'
Search Results
102. Petrolatum: Barrier repair and antimicrobial responses underlying this “inert” moisturizer
103. Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis
104. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization
105. Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing
106. Early pediatric atopic dermatitis shows only a cutaneous lymphocyte antigen (CLA)+ TH2/TH1 cell imbalance, whereas adults acquire CLA+ TH22/TC22 cell subsets
107. Inflammasome Signaling and Impaired Vascular Health in Psoriasis
108. Multi-omics segregate different transcriptomic impacts of anti-IL-17A blockade on type 17 T-cells and regulatory immune cells in psoriasis skin.
109. Hyperactivation of the JAK2/STAT5 Signaling Pathway and Evaluation of Baricitinib Treatment Among Patients With Eosinophilic Cellulitis.
110. Psoriasis and Other Skin Inflammatory Diseases
111. Severe atopic dermatitis is characterized by selective expansion of circulating TH2/TC2 and TH22/TC22, but not TH17/TC17, cells within the skin-homing T-cell population
112. Anti–IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial
113. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications
114. Patients with atopic dermatitis have attenuated and distinct contact hypersensitivity responses to common allergens in skin
115. The translational revolution and use of biologics in patients with inflammatory skin diseases
116. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection
117. Unique protein signatures evolve during the course of a delayed‐type hypersensitivity reaction in human skin
118. Skin proteomic analysis of immune activation associated with regression of melanoma metastases induced by diphencyprone
119. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata
120. Immunosuppression causes dynamic changes in expression QTLs in psoriatic skin
121. Delayed type hypersensitivity reactions to various allergens may differently model inflammatory skin diseases
122. Analysis of alopecia areata surveys suggests a threshold for improved patient-reported outcomes
123. Autoimmunity in Psoriasis: Evidence for Specific Autoantigens
124. Survival of tissue-resident memory T cells requires exogenous lipid uptake and metabolism
125. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis
126. Accumulating Evidence for the Association and Shared Pathogenic Mechanisms Between Psoriasis and Cardiovascular-related Comorbidities
127. IL-23/TH17 Pathway in Psoriasis and Inflammatory Skin Diseases
128. Generalized pustular psoriasis is a disease distinct from psoriasis vulgaris: evidence and expert opinion
129. Raising the bar for efficacy in hidradenitis suppurativa: a rationale for combination targeted therapies
130. 33226 Analysis of histologic and molecular improvement in moderate-to-severe psoriasis: Results from a phase 1b trial of the novel allosteric Tyk2 inhibitor NTX-973
131. The imbalance between Type 17 T-cells and regulatory immune cell subsets in psoriasis vulgaris
132. Molecular profiling of contact dermatitis skin identifies allergen-dependent differences in immune response
133. Skin Barrier and Immune Dysregulation in Atopic Dermatitis: An Evolving Story with Important Clinical Implications
134. Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis
135. Interleukin‐17 alters the biology of many cell types involved in the genesis of psoriasis, systemic inflammation and associated comorbidities
136. Interleukin-17 Inhibition for the Treatment of Inflammatory Skin Disease
137. Immunology
138. Autoantigens ADAMTSL5 and LL37 are significantly upregulated in active Psoriasis and localized with keratinocytes, dendritic cells and other leukocytes
139. Clinically resolved psoriatic lesions contain psoriasis-specific IL-17–producing αβ T cell clones
140. Unique protein signatures evolve during the course of a delayed‐type hypersensitivity reaction in human skin.
141. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata.
142. Cutaneous Adverse Events in the Randomized, Double-Blind, Active-Comparator DECIDE Study of Daclizumab High-Yield Process Versus Intramuscular Interferon Beta-1a in Relapsing-Remitting Multiple Sclerosis
143. Interleukin‐17RA blockade by brodalumab decreases inflammatory pathways in hidradenitis suppurativa skin and serum
144. Molecular and clinical effects of selective tyrosine kinase 2 inhibition with deucravacitinib in psoriasis
145. Ustekinumab reduces serum protein levels associated with cardiovascular risk in psoriasis vulgaris
146. Pustular psoriasis: Molecular pathways and effects of spesolimab in generalized pustular psoriasis
147. Su1743 GUSELKUMAB BINDING TO CD64+ IL-23–PRODUCING MYELOID CELLS ENHANCES POTENCY FOR NEUTRALIZING IL-23 SIGNALING
148. Psoriasis pathogenesis and the development of novel targeted immune therapies
149. Patch testing of food allergens promotes Th17 and Th2 responses with increased IL‐33: a pilot study
150. Efficacy and safety of ustekinumab treatment in adults with moderate‐to‐severe atopic dermatitis
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.